Phase II Study of Bendamustine and Rituximab Induction Chemoimmunotherapy With Maintenance Lenalidomide and Rituximab in Relapsed/Refractory CLL/SLL.
Phase of Trial: Phase II
Latest Information Update: 17 Jul 2017
At a glance
- Drugs Bendamustine (Primary) ; Lenalidomide (Primary) ; Rituximab (Primary)
- Indications Chronic lymphocytic leukaemia
- Focus Therapeutic Use
- 21 Apr 2016 Status changed from active, no longer recruiting to completed.
- 14 May 2015 Planned primary completion date changed from 1 Jul 2018 to 1 Apr 2014 recruiting as reported by ClinicalTrials.gov.
- 22 Jan 2015 According to the the ClinicalTrials.gov record, planned end date changed from 1 Mar 2017 to 1 Jul 2018.